PROVENGE HELPS PATIENTS WITH ADVANCED PROSTATE CANCER

Dendreon has announced that the analysis of the final three-year survival data of its second Phase III study of Provenge-an investigational active immunotherapy for the treatment of prostate cancer-showed a survival benefit in men with advanced prostate cancer who were treated with Provenge. Prostate cancer is the most commonly diagnosed non-skin cancer in the U.S. and the third most common cancer worldwide.

In the study, the three-year final survival analysis in the intent-to-treat population of the double-blind, placebo-controlled study of Provenge in 98 men with asymptomatic, metastatic, androgen-independent (hormone-refractory) prostate cancer showed a 20 percent improvement in median survival, compared to a placebo. In addition, at the three-year final follow up, the percentage of patients alive in the Provenge-treated group was substantially greater than the percentage of patients alive who received a placebo.